Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 receptor agonist effects on pneumococcal vaccine response in type 2 diabetes
NL-OMON61402Phase 4Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of liraglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Radboud University Medical Center. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON61402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61402.